The Latest
HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit Of ORPATHYS® Plus TAGRISSO® In Treatment-Naïve Patients With MET-Overexpressing EGFR-mutated Lung Cancer In China
HUTCHMED announces that the SANOVO trial shows notable progression-free survival benefits for ORPATHYS® combined with TAGRISSO® in untreated MET-overexpressing EGFR-mutant lung cancer patients in China.